FY2025 Earnings Forecast for Neurocrine Biosciences, Inc. Issued By Leerink Partnrs (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Stock analysts at Leerink Partnrs increased their FY2025 earnings estimates for Neurocrine Biosciences in a research note issued to investors on Wednesday, May 1st. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of $6.90 per share for the year, up from their prior forecast of $6.65. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.78 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences’ FY2026 earnings at $9.30 EPS, FY2027 earnings at $10.90 EPS and FY2028 earnings at $12.40 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. The company’s quarterly revenue was up 25.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.88 EPS.

Several other equities research analysts also recently commented on NBIX. Barclays increased their price objective on Neurocrine Biosciences from $150.00 to $169.00 and gave the company an “overweight” rating in a report on Thursday. Citigroup upped their target price on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the company a “neutral” rating in a report on Friday. HC Wainwright lifted their price target on Neurocrine Biosciences from $150.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday. Oppenheimer boosted their price target on Neurocrine Biosciences from $200.00 to $216.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Mizuho lifted their target price on Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a research note on Thursday, February 8th. Six equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus target price of $147.88.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $140.71 on Monday. The stock has a market capitalization of $14.16 billion, a PE ratio of 38.76 and a beta of 0.28. Neurocrine Biosciences has a 52 week low of $89.04 and a 52 week high of $148.37. The stock has a 50 day moving average price of $137.37 and a 200 day moving average price of $129.00.

Insiders Place Their Bets

In other news, insider David W. Boyer sold 1,328 shares of the company’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $135.41, for a total transaction of $179,824.48. Following the completion of the sale, the insider now directly owns 4,895 shares in the company, valued at approximately $662,831.95. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Neurocrine Biosciences news, insider Ingrid Delaet sold 5,000 shares of the company’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $145.06, for a total transaction of $725,300.00. Following the completion of the sale, the insider now directly owns 7,507 shares in the company, valued at $1,088,965.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David W. Boyer sold 1,328 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $135.41, for a total value of $179,824.48. Following the completion of the sale, the insider now directly owns 4,895 shares in the company, valued at approximately $662,831.95. The disclosure for this sale can be found here. Insiders have sold a total of 181,547 shares of company stock worth $25,039,887 in the last 90 days. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds have recently made changes to their positions in the stock. Mather Group LLC. bought a new position in Neurocrine Biosciences in the 1st quarter valued at approximately $26,000. Headinvest LLC bought a new position in shares of Neurocrine Biosciences in the 3rd quarter valued at $28,000. Lindbrook Capital LLC boosted its holdings in shares of Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock valued at $28,000 after acquiring an additional 96 shares in the last quarter. EdgeRock Capital LLC bought a new stake in Neurocrine Biosciences during the 4th quarter worth $31,000. Finally, Benjamin F. Edwards & Company Inc. acquired a new position in Neurocrine Biosciences in the 4th quarter worth about $33,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.